Compare Revvity Inc (RVTY) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Uranium Energy Corp — how do they compare? Revvity Inc trades at $154.34 (market cap $16.98B), while Uranium Energy Corp trades at $9.17 (market cap $4.53B). The key difference: Revvity Inc is far larger — about 3.7× Uranium Energy Corp's market cap, and Revvity Inc pays a 0.18% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Uranium Energy Corp for 37 Days on average.
| RVTY | UEC | |
|---|---|---|
Market Cap | $16.98B | $4.53B |
Volume | 1,456,900 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $157.36 | $20.14 |
52-Week Low | $82.26 | $9.04 |
Typical Hold Time | 12 Days | 37 Days |
Enterprise Value | $19.30B | $4.03B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
UEC trades at $9.27, down 2.11% on the day, amid a bearish technical outlook with 18 sell signals versus 2 buy signals. The company reported a net loss of $87.66 million in 2025, with revenue of $66.84 million, and a negative net income margin of -368.62%. Recent news highlights operational expansion with two in-situ recovery mines ramping up production, supported by strong institutional analyst sentiment with 7 buy ratings and a consensus price target of $16.06.
The investment case balances Wall Street optimism against weak profitability and cash burn. Upside is driven by exposure to growing U.S. uranium demand and multi-mine expansion, but high execution risk, sustained losses, and negative operating cash flow pose significant threats to shareholder value. The stock's trajectory hinges on translating production growth into sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
